Gold Nanoparticle-Mediated Lateral Flow Assays for Detection of Host Antibodies and COVID-19 Proteins
Research output: Contribution to journal › Review › peer-review
Documents
- Fulltext
Final published version, 931 KB, PDF document
Coronaviruses, that are now well-known to the public, include a family of viruses that can cause severe acute respiratory syndrome (SARS) and other respiratory diseases, such as Middle East respiratory syndrome (MERS). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the seventh member of this coronavirus family, was detected in 2019 and can cause a number of respiratory symptoms, from dry cough and fever to fatal viral pneumonia. Various diagnostic assays ranging from real-time polymerase chain reaction (RT-PCR) to point-of-care medical diagnostic systems have been developed for detection of viral components or antibodies targeting the virus. Point-of-care assays allow rapid diagnostic assessment of infectious patients. Such assays are ideally sim-ple, low-cost, portable tests with the possibility for on-site field detection that do not require skilled staff, sophisticated equipment, or sample pretreatment, as compared to RT-PCR. Since early 2021 when new SARS-CoV-2 variants of concern increased, rapid tests became more crucial in the disease management cycle. Among rapid tests, gold nanoparticle (GNP)-based lateral flow assays (LFAs) have high capacity for performing at the bedside, paving the way to easy access to diagnosis results. In this review, GNP-based LFAs used for either COVID-19 proteins or human response antibodies are summarized and recommendations for their improvement have been suggested.
Original language | English |
---|---|
Article number | 1456 |
Journal | Nanomaterials |
Volume | 12 |
Issue number | 9 |
Number of pages | 17 |
ISSN | 1687-4110 |
DOIs | |
Publication status | Published - 1 May 2022 |
Bibliographical note
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
- antibody test, antigen test, gold nanoparticle, immuno-chromatography, lateral flow assay, SARS-CoV-2
Research areas
ID: 307754711